Palvella Therapeutics And Pieris Pharmaceuticals To Merge, Creating A Nasdaq-Listed Entity With $80.5M Cash To Drive Development Of Novel Skin Disease Therapies
Portfolio Pulse from Benzinga Newsdesk
Palvella Therapeutics and Pieris Pharmaceuticals are merging to form a Nasdaq-listed biopharmaceutical company with $80.5M in cash. The combined entity will focus on developing treatments for rare genetic skin diseases, including QTORIN™ rapamycin for microcystic lymphatic malformations.
July 24, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pieris Pharmaceuticals is merging with Palvella Therapeutics to form a Nasdaq-listed company with $80.5M in cash. The merger aims to advance treatments for rare genetic skin diseases, including QTORIN™ rapamycin.
The merger is expected to provide significant financial resources and strategic focus on developing treatments for rare skin diseases, which could drive positive sentiment and stock price appreciation for PIRS.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100